Uncategorized

Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset

Published

on

Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version